QQQ   319.26 (-1.34%)
AAPL   125.22 (-2.01%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,093.51 (-1.67%)
NVDA   539.35 (-2.59%)
BABA   235.11 (-2.72%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.20 (-13.18%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.63 (+5.43%)
ACB   11.06 (+0.18%)
DIS   193.86 (-0.57%)
BA   223.93 (-0.21%)
NFLX   548.09 (-0.46%)
BAC   35.67 (-0.34%)
QQQ   319.26 (-1.34%)
AAPL   125.22 (-2.01%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,093.51 (-1.67%)
NVDA   539.35 (-2.59%)
BABA   235.11 (-2.72%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.20 (-13.18%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.63 (+5.43%)
ACB   11.06 (+0.18%)
DIS   193.86 (-0.57%)
BA   223.93 (-0.21%)
NFLX   548.09 (-0.46%)
BAC   35.67 (-0.34%)
QQQ   319.26 (-1.34%)
AAPL   125.22 (-2.01%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,093.51 (-1.67%)
NVDA   539.35 (-2.59%)
BABA   235.11 (-2.72%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.20 (-13.18%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.63 (+5.43%)
ACB   11.06 (+0.18%)
DIS   193.86 (-0.57%)
BA   223.93 (-0.21%)
NFLX   548.09 (-0.46%)
BAC   35.67 (-0.34%)
QQQ   319.26 (-1.34%)
AAPL   125.22 (-2.01%)
MSFT   234.58 (-1.00%)
FB   260.45 (-1.68%)
GOOGL   2,067.00 (-0.13%)
TSLA   686.37 (-4.46%)
AMZN   3,093.51 (-1.67%)
NVDA   539.35 (-2.59%)
BABA   235.11 (-2.72%)
CGC   35.01 (+0.81%)
GE   13.02 (-0.69%)
MU   91.64 (-3.29%)
NIO   43.20 (-13.18%)
AMD   84.71 (-1.94%)
T   28.36 (+0.96%)
F   12.63 (+5.43%)
ACB   11.06 (+0.18%)
DIS   193.86 (-0.57%)
BA   223.93 (-0.21%)
NFLX   548.09 (-0.46%)
BAC   35.67 (-0.34%)
Log in

Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 MesoblastTaysha Gene TherapiesPassage BioVaxcyteSutro Biopharma
SymbolNASDAQ:MESONASDAQ:TSHANASDAQ:PASGNASDAQ:PCVXNASDAQ:STRO
Price Information
Current Price$9.25$25.37$19.55$26.01$22.41
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score1.41.81.91.81.1
Analysis Score3.13.54.33.51.4
Community Score3.14.03.03.22.4
Dividend Score0.00.00.00.00.0
Ownership Score0.00.81.71.71.7
Earnings & Valuation Score0.60.60.60.60.0
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$14.55$37.83$25.24$48.00$23.33
% Upside from Price Target57.30% upside49.13% upside29.13% upside84.54% upside4.12% upside
Trade Information
Market Cap$1.13 billion$1.01 billion$896.30 million$1.32 billion$887.89 million
Beta3.71N/AN/AN/A0.8
Average Volume930,32275,249524,646363,226508,664
Sales & Book Value
Annual Revenue$32.16 millionN/AN/AN/A$42.74 million
Price / Sales33.80N/AN/AN/A20.24
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$4.70 per shareN/AN/AN/A$4.24 per share
Price / Book1.97N/AN/AN/A5.29
Profitability
Net Income$-77,940,000.00N/AN/A$-50,270,000.00$-55,740,000.00
EPS($0.74)N/AN/AN/A($2.43)
Trailing P/E RatioN/A0.000.000.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-591.00%N/AN/AN/A27.60%
Return on Equity (ROE)-18.69%N/AN/AN/A-41.86%
Return on Assets (ROA)-13.85%N/AN/AN/A-29.50%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.10%N/AN/AN/A0.10%
Current Ratio1.32%24.02%18.30%10.12%9.77%
Quick Ratio1.32%24.02%18.30%10.12%9.77%
Ownership Information
Institutional Ownership Percentage2.80%42.19%67.59%74.08%78.80%
Insider Ownership Percentage18.80%N/AN/AN/A28.90%
Miscellaneous
Employees102N/A2043182
Shares Outstanding117.52 million37.76 million45.92 million50.95 million38.60 million
Next Earnings Date3/3/2021 (Estimated)3/3/2021 (Confirmed)3/3/2021 (Confirmed)3/4/2021 (Estimated)3/15/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.